Guardian Bio
New accelerator entry · 2022-07-06 · the record
In their words
Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. Our therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.
What the record says
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Guardian Bio
- Source Check — verify what Guardian Bio states, against the registers that hold it.
- INVEST — size up this company on the figures its record states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Guardian Bio for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Guardian BioYou get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Guardian Bio: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.